SurePath™ Pap with Reflex to HPV DNA
Use
Liquid‑based Pap testing is intended for use in the screening and detection of cervical cancer, precancerous lesions, atypical cells and all other cytologic categories as defined by the Bethesda System for Reporting Results of Cervical Cytology. Pap screening is not reliable for the detection of endometrial cancer.
Special Instructions
If SurePath™ Pap result is ASCUS, HPV DNA, High Risk will be performed at an additional charge. Pap results requiring physician interpretation will be performed at an additional charge. For specimen collection instructions refer to Specimen Collection and Transport Guide (2019).
Limitations
Not provided.
Methodology
Other
Biomarkers
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (Unknown)
Volume
Not provided
Minimum Volume
1 SurePath pap vial
Container
SurePath™ pap vial
Collection Instructions
Pap sample collected in 1 (1 minimum) SurePath™ pap vial
Causes for Rejection
SurePath™ vials without the head of the collection device(s) in the fluid; SurePath™ vials received frozen; swabs; cervical swabs in Digene® HC cervical sampler, Digene® vials; vaginal sources
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 28 days |
| Refrigerated | 6 months |
| Frozen | Unacceptable |